Biotechnology

Oruka Therapeutics

Oruka Therapeutics Executive Arjun Agarwal Sells 10,290 Common Shares

Oruka Therapeutics released FY2026 Q1 earnings on May 13 Post-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4777 (forecast USD -0.554)

Analyst Maintains Buy Rating on ORKA Stock

Oruka Therapeutics' Psoriasis Drug Meets Mid-Stage Study Goal

Oruka Therapeutics released FY2025 annual earnings on March 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.8483 (forecast USD -2.1615)

Oruka Therapeutics released FY2025 Q4 earnings on March 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4492 (forecast USD -0.6208)

Oruka Therapeutics released FY2025 9 Months Earnings on November 12, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.4

Oruka Therapeutics released FY2025 Q3 earnings on November 12 (EST) with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD 0 (forecast USD -0.5342)

Oruka Therapeutics released FY2025 Q2 earnings on August 11 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD -0.4591 (forecast USD -0.485)

Oruka Therapeutics released FY2025 Semi-Annual earnings on August 11, 2025, EST with actual revenue USD 0 and EPS USD -0.8547

Oruka Therapeutics released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3953 (forecast USD -0.44)

Oruka Therapeutics released FY2024 annual earnings on March 6 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -4.2258 USD (forecast -3.2083 USD)

Oruka Therapeutics released FY2024 Q4 earnings on March 6, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4877 (forecast USD -0.4133)

Oruka Therapeutics released FY2024 Q3 earnings on November 13 (EST), actual revenue 0 USD, actual EPS -1.461 USD (forecast EPS -0.384 USD)

Oruka Therapeutics released FY2024 9 Months Earnings on November 13 (EST) with actual revenue of USD 0 and EPS of USD -51.3661

Oruka Therapeutics released FY2024 Q2 earnings on September 5 (EST), actual revenue USD 0, actual EPS USD -6.9553

Oruka Therapeutics released FY2024 Semi-Annual Earnings on September 5, with actual revenue of 0 USD and EPS of -62.8662 USD

Oruka Therapeutics released FY2024 Q1 earnings on July 22 (EST) with actual revenue of USD 0 and EPS of USD -2.2129

Amesite

InMed Pharmaceuticals

Meiwu Tech

Co-Diagnostics

Phoenix Asia

Generation Income Properties

Rubico

MetaVia

Virax Biolabs

Hub Cyber Security

ORKA

IBBQ

ARKG

LABU

Oruka Therapeutics SVP Arjun Agarwal sold 10,290 shares at $59.07 each, totaling $607,830.30, representing a 38.55% decrease in his ownership. Post-sale, he holds 16,406 shares valued at $969,102.42. The transaction was made under a Rule 10b5-1 plan and disclosed to the SEC. The stock is currently trading down 5.8% at $58.34.

Market Beat

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Barclays

UBS Group AG

ROYAL BANK OF CANADA

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock

Barclays analyst Etzer Darout has maintained a Buy rating on Oruka Therapeutics (ORKA) with a price target of $160.00. Darout, a 5-star analyst with a 26.4% average return and 56.04% success rate, focuses on the Healthcare sector. The consensus on Oruka Therapeutics is a Strong Buy, with an average price target of $128.50.

Tip Ranks

iShares US Pharma

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Incyte

Legend Biotech

Jazz Pharma

Barclays Remains a Buy on Oruka Therapeutics (ORKA)

TD Cowen analyst Tyler Van Buren has maintained a Buy rating on ORKA stock, citing strong clinical data for ORKA-001 in psoriasis, which showed a 64% PASI 100 response. Oruka's robust financial position, with $1.2 billion in cash, supports the development of ORKA-001 without immediate financing needs. Upcoming Phase IIa data and the Phase IIb EVERLAST-B readout in 2027 are expected to further validate its potential, which is estimated to be multi-billion-dollar. H.C. Wainwright also reiterated a Buy rating with a $120 price target.

- TD Cowen analyst Tyler Van Buren has maintained a bullish stance on ORKA stock, issuing a buy rating on May 8.  
- He cites the strong clinical characteristics of ORKA-001, achieving a 64% PASI 100 response in psoriasis trials, paired with Oruka's solid financial position, including approximately $1.2 billion in cash.  
- Van Buren anticipates that upcoming data releases will further validate ORKA-001's market potential, supported by another buy rating from H.C. Wainwright with a target price of $120.00.

Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential

Earnings Watch

Oruka Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

HALO

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Halozyme Therap

iShares US Medical Devices

SPDR S&P Health Equip

Halozyme and Oruka sign agreement for Hypercon technology

Oruka Therapeutics shares are trading lower after the company priced an upsized $700 million public offering of 9.66 million shares at $72.50 per share.

benzinga_article

Oruka Therapeutics (ORKA.US) current price $68.125, down 7.93% for the day, intraday drop below 8%, market capitalization $3.41 billion. The company recently announced an expansion of its underwritten public offering to $700 million, putting short-term pressure on the market. As a biopharmaceutical company, institutions are cautiously responding to the adjustment of the capital structure, and there are currently no other significant catalysts

Movers Alert

Oruka Therapeutics Drops 7.9% After Stock Offering

Oruka Therapeutics(ORKA.US)